AAAAAA
Results:
1-12
|
Results: 12
Authors:
Vansteenkiste, J
Gatzemeier, U
Manegold, C
Hanauske, A
Weynants, P
Bosquee, L
Blatter, J
Mansouri, K
von Pawel, J
Citation: J. Vansteenkiste et al., Gemcitabine plus etoposide in chemonaive extensive disease small-cell lungcancer: A multi-centre phase II study, ANN ONCOL, 12(6), 2001, pp. 835-840
Authors:
von Pawel, J
Gatzemeier, U
Pujol, JL
Moreau, L
Bildat, S
Ranson, M
Richardson, G
Steppert, C
Riviere, A
Camlett, I
Lane, S
Ross, G
Citation: J. Von Pawel et al., Phase II comparator study of oral versus intravenous topotecan in patientswith chemosensitive small-cell lung cancer, J CL ONCOL, 19(6), 2001, pp. 1743-1749
Authors:
Pujol, JL
von Pawel, J
Tumolo, S
Martoni, A
Hearn, S
Fields, SZ
Ross, G
Citation: Jl. Pujol et al., Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer, ONCOL-BASEL, 61, 2001, pp. 47-54
Authors:
Manegold, C
Gatzemeier, U
von Pawel, J
Pirker, R
Malayeri, R
Blatter, J
Krejcy, K
Citation: C. Manegold et al., Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA (TM)) and cisplatin: A multicenter phase II trial, ANN ONCOL, 11(4), 2000, pp. 435-440
Authors:
Bokemeyer, C
Hartmann, JT
Mayer, F
Bohlke, I
Kanz, L
von Pawel, J
Derigs, G
Schroder, M
Citation: C. Bokemeyer et al., UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors, ONCOLOGY-NY, 14(10), 2000, pp. 63-67
Authors:
von Pawel, J
von Roemeling, R
Gatzemeier, U
Boyer, M
Elisson, LO
Clark, P
Talbot, D
Rey, A
Butler, TW
Hirsh, V
Olver, I
Bergman, B
Ayoub, J
Richrdson, G
Dunlop, D
Arcenas, A
Vescio, R
Viallet, J
Treat, J
Citation: J. Von Pawel et al., Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group, J CL ONCOL, 18(6), 2000, pp. 1351-1359
Authors:
Gatzemeier, U
von Pawel, J
Gottfried, M
ten Velde, GPM
Mattson, K
DeMarinis, F
Harper, P
Salvati, F
Robinet, G
Lucenti, A
Bogaerts, J
Gallant, G
Citation: U. Gatzemeier et al., Phase III comparative study of high-dose cisplatin versus a combination ofpaclitaxel and cisplatin in patients with advanced non-small-cell lung cancer, J CL ONCOL, 18(19), 2000, pp. 3390-3399
Authors:
Sandler, AB
Nemunaitis, J
Denham, C
von Pawel, J
Cormier, Y
Gatzemeier, U
Mattson, K
Manegold, C
Palmer, MC
Gregor, A
Nguyen, B
Niyikiza, C
Einhorn, LH
Citation: Ab. Sandler et al., Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer, J CL ONCOL, 18(1), 2000, pp. 122-130
Authors:
Huber, RM
Gatzemeier, U
Gosse, H
von Pawel, J
Hruska, D
Mezger, J
Saal, JG
Kleinschmidt, R
Steppert, C
Steppling, H
Citation: Rm. Huber et al., Topotecan in second-line therapy of SCLC: Impact on survival?, ONKOLOGIE, 23, 2000, pp. 9-12
Authors:
Gatzemeier, U
Kleisbauer, JP
Drings, P
Kaukel, E
Samaras, N
Melo, MJ
Cardenal, F
Robinet, G
Snijder, RJ
von Pawel, J
Palisses, R
Citation: U. Gatzemeier et al., Lenograstim as support for ACE chemotherapy of small-cell lung cancer - A phase III, multicenter, randomized study, AM J CL ONC, 23(4), 2000, pp. 393-400
Authors:
von Pawel, J
Schiller, JH
Shepherd, FA
Fields, SZ
Kleisbauer, JP
Chrysson, NG
Stewart, DJ
Clark, PI
Palmer, MC
Depierre, A
Carmichael, J
Krebs, JB
Ross, G
Lane, SR
Gralla, R
Citation: J. Von Pawel et al., Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer, J CL ONCOL, 17(2), 1999, pp. 658-667
Authors:
Huinink, WWT
Bergman, B
Chemaissani, A
Dornoff, W
Drings, P
Kellokumpu-Lehtinen, PL
Liippo, K
Mattson, K
von Pawel, J
Ricci, S
Sederholm, C
Stahel, RA
Wagenius, G
von Walree, N
Manegold, C
Citation: Wwt. Huinink et al., Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer, LUNG CANC, 26(2), 1999, pp. 85-94
Risultati:
1-12
|